Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sekar Kathiresan Insider Profile
4 Followers
Sekar Kathiresan, CEO, Director at Verve Therapeutics, holds 675.50K shares in Verve Therapeutics (Ticker: VERV), holds ― shares in Relay Therapeutics (Ticker: RLAY).
Sekar Kathiresan has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Sekar Kathiresan holds in companies
Most Profitable Insider Trade
The most profitable trade made by Sekar Kathiresan
Sekar Kathiresan's Trading History
Verve Therapeutics
Dec 04, 2024
CEO, Director
Uninformative Sell
―
$5.20M
Relay Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Sekar Kathiresan's performance on stock
You May Also Like
Sekar Kathiresan insider profile FAQ
What is the percentage of profitable transactions made by Sekar Kathiresan?
The percentage of profitable transactions made by Sekar Kathiresan is ―.
What is the average return per transaction made by Sekar Kathiresan?
The average return per transaction made by Sekar Kathiresan is ―.
What stocks does Sekar Kathiresan hold?
Sekar Kathiresan holds: VERV, RLAY stocks.
What was Sekar Kathiresan’s latest transaction?
Sekar Kathiresan latest transaction was an Uninformative Sell of ―.
What was Sekar Kathiresan's most profitable transaction?
Sekar Kathiresan’s most profitable transaction was an Informative Buy of VERV stock on June 21, 2021. The return on the trade was -64.70%.
What is Sekar Kathiresan's role in Verve Therapeutics?
Sekar Kathiresan's role in Verve Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.